Systematic Review and Meta-Analysis of Thiopurine Metabolite Levels and Biochemical Remission in Autoimmune Hepatitis
- 17 December 2020
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Therapeutic Drug Monitoring
- Vol. 43 (5), 609-616
- https://doi.org/10.1097/ftd.0000000000000848
Abstract
Objectives and study: The utility of measuring thiopurine metabolites (TM) to individualize therapy in autoimmune hepatitis (AIH) has not been defined, and the evidence regarding its use in clinical practice is heterogeneous. This systematic review and meta-analysis aimed to compare the mean concentration of TM between patients in biochemical remission and those not in remission. Methods: A systematic literature search was conducted using PubMed, Scopus, the Cochrane Library, and Google Scholar for keywords related to TM and AIH. Two reviewers independently searched and selected studies comparing the levels of 6-methyl mercaptopurine (6-MMP) and 6-thioguanine nucleotide (6-TGN) and their ratio in cases of AIH in remission and otherwise. Meta-analysis was performed by calculating the weighted mean difference using the inverse variance heterogeneity model. Results: A total of 1066 records were identified through systematic search, of which 7 (n = 3 pediatric, n = 4 adults) were considered for inclusion and 442 TM measurements (n = 128 in children) were analyzed. Mean 6-TGN levels were significantly higher among patients in remission than in those who were not, with a pooled weighted mean difference (WMD) of 15.67 [95% confidence interval (CI), 6.68–24.66] pmol/8 × 108 red blood cells (RBC). The difference was higher in the pediatric age group [WMD 56.11, 95% CI: 13.60–98.62] than in adults [WMD 13.77, 95% CI: 4.58–22.97]. There was no significant difference in the 6-MMP levels (WMD -431.7, 95% CI:-1237.4–373.9 pmol/8 × 108 RBC, I2 = 82%, n = 3 studies) or 6-MMP/6-TGN ratio among the patients who were in biochemical remission and those who were not (WMD -0.97, 95% CI: -5.77–3.84, I2 = 82%, n = 3 studies]. Conclusions: This meta-analysis suggests a link between 6-TGN levels and biochemical remission in AIH. Further high-quality studies are required to determine the therapeutic cut-off of 6-TGN.Keywords
This publication has 20 references indexed in Scilit:
- Association Between 6-Thioguanine Nucleotides Levels and Clinical Remission in Inflammatory DiseaseInflammatory Bowel Diseases, 2014
- Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitisJournal of Hepatology, 2012
- Azathioprine metabolite measurements are not useful for following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian peopleCanadian Journal of Gastroenterology, 2011
- Monitoring of Azathioprine Metabolites in Pediatric Patients With Autoimmune HepatitisTherapeutic Drug Monitoring, 2010
- Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitisJournal of Hepatology, 2009
- Safety issues in the management of autoimmune hepatitisExpert Opinion on Drug Safety, 2008
- Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver diseaseJournal of Hepatology, 2007
- Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitisJournal of Hepatology, 2006
- Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel diseaseGut, 2004
- Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseGut, 2001